Tag Archives: Alzheimer’s Disease

Senior Send-Off: The Synapto Team

In our Senior Send-Off series, the Dingman Center celebrates the student founders who are part of the graduating class of Spring 2020. We are so pleased to have had the chance to get to know each of these talented entrepreneurs through our programs. 


From left: Chris Look, Anoop Patel, Megha Guggari, David Boegner, Dhruv Patel

SynaptoLogo on white_White BkgrdSynapto

Co-founder & CEO – Dhruv Patel ’20, Bioengineering major
Co-founder & CTO – Christopher Look ’20, Bioengineering major
Lead Systems Engineer – David Boegner ’20, Bioengineering major
Lead Software Engineer – Megha Guggari ’20, Bioengineering major
Lead R&D Engineer – Anoop Patel ’20, Bioengineering major

The Synapto team is made up of five University of Maryland bioengineering majors who are using a portable EEG and machine learning to provide doctors with a more efficient tool to diagnose Alzheimer’s. Having worked on this idea since 2017, the team has achieved many milestones along the way, including a prize from NIH, second place at the 2018 Do Good Challenge, and third place at the 2019 Pitch Dingman Competition Finals. The Dingman Center has had numerous opportunities to watch these founders grow: Chris Look enrolled in our Terp Startup accelerator for a different idea, Senvision, as a freshman; David Boegner and Anoop Patel represented Synapto in the 2018 Terp Startup cohort; and Megha Guggari was part of the first cohort of Ladies First Founders. The Synapto team took home our Rudy Award for Social Entrepreneurs of the Year in 2019, and we are excited to see how these impressive founders continue to shine post-graduation.

Continue reading

Tagged , , ,

An Interview With Pitch Dingman Competition Finalist: Synapto

In anticipation of the final round of the 2019 Pitch Dingman Competition, the Dingman Center is interviewing each of the five startup finalists about their progress and upcoming challenges as they prepare to compete for the $15,000 Grand Prize on March 7th in the Grand Ballroom of Stamp Student Union. Learn more and register to attend the competition here.


Christopher Look and Megha Guggari


Dhruv Patel ’20, CEO
Chris Look ’20, CTO
Anoop Patel ’20, Lead R&D Engineer
David Boegner ’20, Lead Systems Engineer
Megha Guggari ’20, Lead Software Engineer

DC: Tell us about your startup. Synapto.png

Synapto: Synapto is using next generation brainwave scanning technologies in conjunction with AI to make Alzheimer’s diagnosis more accessible, streamlined, and effective.

DC: Have there been some key decisions or milestones along the way that have led you from an idea to now pitching for $15K?

Synapto: We’ve been working on this for about 2 years now, and have been recognized by several institutions like NIH and media outlets like Forbes. Recognizing our methods are worth pursuing has led us to pitch for $15,000 to help further drive product development.

Continue reading

Tagged , ,

Terp Startup Synapto Looks to Change the Game for Diagnosing Alzheimer’s

This summer, the Dingman Center will be conducting interviews with the ten student startups who are participating in the Terp Startup summer accelerator phase of our Fearless Founders program. Participating student entrepreneurs received a stipend up to $5,000 that would enable them to work exclusively on their startups over eight weeks in the summer.


Synapto co-founders Anoop Patel and David Boegner


Co-Founder and Lead Machine Learning Engineer: Anoop Patel ’20, Bioengineering major, Computer Science minor
Co-Founder and Lead Systems Engineer: David Boegner ’20, Bioengineering major

Not in Terp Startup:
Co-Founder and CEO: Dhruv Patel ’20, Bioengineering major
Co-Founder and CTO: Chris Look ’20, Bioengineering, Computer Science double major
Co-Founder and Lead Software Engineer: Megha Guggari, ’20, Computer Science major

DC: Tell us about your startup. What problem are you solving and for whom?

Synapto: Synapto is an early stage biotech venture aiming to revolutionize the diagnosis of Alzheimer’s Disease through portable electroencephalogram (EEG) and machine learning. This technology allows for a cheaper, faster and more quantitative method of detection in comparison to current qualitative questionnaires and costly neuroimaging techniques (PET, MRI). Detecting the disease earlier allows more time for financial and legal planning, and provides the opportunity to enter clinical trials sooner, improving the drug development landscape.

Continue reading

Tagged , , , , ,